Combining blinatumomab and donor lymphocyte infusion in B-ALL patients relapsing after allogeneic hematopoietic cell transplantation: a study of the SFGM-TC

Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia

(2021) Franco Locatelli et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia

(2021) Andrew H. Wei et al.   LEUKEMIA

Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant

(2021) Cristina Papayannidis et al.   HEMATOLOGICAL ONCOLOGY

KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study

(2021) Bijal D Shah et al.   LANCET

Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia

(2021) Mahmoud R. Gaballa et al.   BLOOD

Reconstitution of T Cell Subsets Following Allogeneic Hematopoietic Cell Transplantation

(2020) Linde Dekker et al.   Cancers

Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

(2019) Anthony S. Stein et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia: a case report with literature review

(2019) Seren Durer et al.   Immunotherapy

Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia

(2019) Amber C. King et al.   LEUKEMIA RESEARCH

Single-center experience suggests donor lymphocyte infusion may promote long-term survival in children with high-risk acute lymphoblastic leukemia

(2019) Nicole Liberio et al.   PEDIATRIC BLOOD & CANCER

Trends in the use of hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia in Europe: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

(2019) Sebastian Giebel et al.   ANNALS OF HEMATOLOGY

Improved Overall Survival, Relapse-Free-Survival, and Less Graft-vs.-Host-Disease in Patients With High Immune Reconstitution of TCR Gamma Delta Cells 2 Months After Allogeneic Stem Cell Transplantation

(2019) Lia Minculescu et al.   Frontiers in Immunology

From clinical proof-of-concept to commercialization of CAR T cells

(2018) Boris Calmels et al.   DRUG DISCOVERY TODAY

Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions

(2018) Guillermo Ortí et al.   EXPERIMENTAL HEMATOLOGY

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

(2017) Sattva S. Neelapu et al.   Nature Reviews Clinical Oncology

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

(2017) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Concurrent blinatumomab and donor lymphocyte infusions for treatment of relapsed pre-B-cell ALL after allogeneic hematopoietic cell transplant

(2016) M Ueda et al.   BONE MARROW TRANSPLANTATION

Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study

(2016) A Desjonquères et al.   Blood Cancer Journal

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report

(2015) Madan H. Jagasia et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of ⩾10 years

(2015) G Andreola et al.   BONE MARROW TRANSPLANTATION

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

(2015) Max S Topp et al.   LANCET ONCOLOGY

Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia

(2015) Josep-Maria Josep-Maria Ribera et al.   OncoTargets and Therapy

A multicentre UK study of GVHD following DLI: Rates of GVHD are high but mortality from GVHD is infrequent

(2014) J J Scarisbrick et al.   BONE MARROW TRANSPLANTATION

Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

(2014) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Outcomes of Adults with Acute Lymphoblastic Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation

(2013) Li Mei Poon et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies

(2013) Najla El-Jurdi et al.   Immunotherapy

Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT

(2012) A Spyridonidis et al.   LEUKEMIA

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

(2011) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY